Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of RBD5044 in Chinese participants with hypertriglyceridemia
CTR20260797Phase 2Active
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of rbd5044 in hypertriglyceridemia, sponsored by Suzhou Ribo Life Science Co., Ltd.. Started Mar 2026; status: active.
02
Drugs
rbd5044
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on CTR20260797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260797.